August 5, 2019 08:50 AM EDT
Pharma

Rac­ing af­ter the lead­ers, Eli Lil­ly's mi­graine drug clears an­oth­er piv­otal study

Natalie Grover

Reporter

A month af­ter se­cur­ing ap­proval for clus­ter headaches, Lil­ly’s $LLY mi­graine drug Em­gal­i­ty has scored in a late-stage tri­al as a pre­ven­tive treat­ment for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times